<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483661</url>
  </required_header>
  <id_info>
    <org_study_id>B-ER-108-058</org_study_id>
    <nct_id>NCT04483661</nct_id>
  </id_info>
  <brief_title>Development of Systems and Precision Medicine - Take Mood Disorder as an Example.</brief_title>
  <official_title>Development of Systems and Precision Medicine - Take Mood Disorder as an Example.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Precision medicine is to achieve individual optimal health care, given the biological&#xD;
      mechanisms, genetic variants, and environmental measurements. Take mood disorder (MD) as an&#xD;
      example, we aim to develop systems and precision medicine in Taiwanese population.&#xD;
&#xD;
      MD is a very serious and dysfunctional mental disorder. Since MD patients with treatment have&#xD;
      high risk of neurocognitive impairment and metabolic disturbances, the therapeutic strategies&#xD;
      are of clinical importance. Individual difference of treatment outcome in MD patients would&#xD;
      result from genetic variants, environmental factors, and their interactions. Also, the&#xD;
      treatment outcome of MD contains multiple dimensions, including improvement of disease&#xD;
      severity, neurocognitive function, and optimized medication strategy. However, comprehensive&#xD;
      development of approaches to investigate the multiple dimensions of treatment outcome in MD&#xD;
      patients is limited. In this three-year proposal, we explore the interactions of genetic&#xD;
      variants and environmental factors (represented by psychosocial stress and gut microbiota)&#xD;
      driven approaches to develop precision medicine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Depression severity</measure>
    <time_frame>six months</time_frame>
    <description>Clinician rated score by Structure Interview Guide for the Hamilton Depression Rating Scale (17-item)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The influence of environmental factor in mood disorder</measure>
    <time_frame>six months</time_frame>
    <description>Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function assessed using the Finger Tapping Test (FTT)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function assessed using Wisconsin Card Sorting Test (WCST)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function assessed using Continuous Performance Test (CPT)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mood Disorders</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who met the criteria will be successively recruited from the National Cheng Kung&#xD;
        University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, 20- 70 years of age&#xD;
&#xD;
          -  Major depression disorder who met the DSM-V diagnostic criteria were enrolled&#xD;
&#xD;
          -  Subjects take at least one kind of antidepressant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Presence of any other major psychiatric illness&#xD;
&#xD;
          -  History of substance and alcohol abuse or dependence&#xD;
&#xD;
          -  Presence of auto-immune disorder and infectious diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cheng Kung University (NCKU) Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Hua Chang, PhD</last_name>
      <phone>886-2353535</phone>
      <phone_ext>5683</phone_ext>
      <email>huihua@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mood disorder, neurocognitive function, metabolic disturbances, microbiota-gut-brain axis, genetic variant, pharmacogenomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

